Seal Biosciences Seal Biosciences Seal Biosciences Seal Biosciences Seal Biosciences

JCI Insight, August 2019, vol.4 Issue 15

  • October 10, 2020
150 150 Seal Biosciences

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Oghenekevwe M. Gbenedio, … , Jeroen P. Roose, Philippe Depeille
CI Insight. 2019;4(15):e127552. https://doi.org/10.1172/jci.insight.127552

Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients with WT KRAS typing are eligible to receive anti-EGFR therapy combined with chemotherapy.

READ MORE

http://www.sealbiosciences.com/wp-content/uploads/2020/10/Gbenedio_EGFR-Organoids_JCI-Insight_Aug-2019-copy1.pdf